CNPR Drug Development Process 5 — Questions and Answers
Question 1: Which phase of drug development is specifically designed to determine the Maximum Tolerated Dose (MTD) and optimal dosing schedule?
- Preclinical animal studies
- Phase I (Correct answer)
- Phase II
- Phase III
Correct answer: Phase I
Phase I trials primarily focus on safety, tolerability, pharmacokinetics, and establishing the MTD, usually in healthy volunteers or in oncology patients.
Question 2: What is the significance of a drug receiving '505(b)(2)' NDA status?
- It means the drug was approved through the accelerated approval pathway for serious conditions
- It allows the application to rely on published literature or prior FDA findings for safety and efficacy data not generated by the sponsor (Correct answer)
- It designates the drug as a biosimilar to an already-approved biologic
- It grants automatic exclusivity for 12 years without patent protection
Correct answer: It allows the application to rely on published literature or prior FDA findings for safety and efficacy data not generated by the sponsor
A 505(b)(2) NDA is a hybrid submission that can reference existing safety/efficacy data from published literature or other approved drugs, reducing development costs.
Question 3: During drug development, 'Good Clinical Practice' (GCP) guidelines ensure:
- That clinical trials are conducted ethically, with accurate data and protection of participants' rights (Correct answer)
- That manufacturing facilities meet FDA cleanliness and quality standards
- That sales representatives follow legal promotional guidelines
- That generic drugs are chemically identical to their brand counterparts
Correct answer: That clinical trials are conducted ethically, with accurate data and protection of participants' rights
GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials involving human subjects.
Question 4: A biosimilar differs from a generic drug primarily because:
- Biosimilars are manufactured outside the US while generics are made domestically
- Biologics are large, complex molecules that cannot be exactly replicated, so biosimilars must demonstrate no clinically meaningful differences rather than chemical identity (Correct answer)
- Biosimilars require a shorter FDA review period than traditional generics
- Generic drugs require new clinical trials while biosimilars do not
Correct answer: Biologics are large, complex molecules that cannot be exactly replicated, so biosimilars must demonstrate no clinically meaningful differences rather than chemical identity
Unlike small-molecule generics that can achieve exact chemical identity, biologics are complex proteins where slight manufacturing differences make exact duplication impossible, requiring biosimilarity rather than sameness.
Question 5: What is 'drug repositioning' (also called drug repurposing)?
- Moving a drug from pharmacy shelves to behind-the-counter status
- Identifying new therapeutic uses for an existing, already-approved drug (Correct answer)
- Reformulating a drug to change its route of administration
- Transferring ownership of a drug patent between companies
Correct answer: Identifying new therapeutic uses for an existing, already-approved drug
Drug repositioning leverages existing safety data by finding new indications for approved drugs, significantly reducing development time and cost compared to de novo development.
Question 6: Which regulatory concept requires that drug manufacturers demonstrate their manufacturing processes consistently produce a product meeting its specifications?
- Pharmacovigilance
- Process Validation (Correct answer)
- Bioequivalence Testing
- Risk Evaluation and Mitigation Strategies (REMS)
Correct answer: Process Validation
Process validation establishes documented evidence that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes.
Question 7: When a pharmaceutical company files a citizen petition to delay a generic drug's approval, the FDA must respond within:
- 30 days
- 90 days
- 150 days (Correct answer)
- 180 days
Correct answer: 150 days
Under FDAAA, the FDA must respond to citizen petitions submitted to delay generic approvals within 150 days, with the response typically issued just before or alongside the generic approval.
CNPR Drug Development Process 5
Which phase of drug development is specifically designed to determine the Maximum Tolerated Dose (MTD) and optimal dosing schedule?